Revolution Medicines posts investor presentation on RASONQUE FDA approval
RVMD•Label and Phase 3 data
- Label: adults with metastatic PDAC with at least one prior systemic therapy, or not candidates for multiagent systemic therapy.
- Phase 3 RASolute 302: median overall survival 13.2 months vs 6.7 months; hazard ratio 0.40.
- Median progression-free survival 7.2 months vs 3.6 months; hazard ratio 0.49.
- Recommended dose 300 mg once daily; serious adverse reactions in 30% of patients.
Investor presentation on FDA approval
Revolution Medicines released an investor presentation covering U.S. FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma.
Related News
Anthropic Has Agreed To Spend $45 Billion To Rent AI Cloud Computing Power From Nscale’s Data Center Development In West Virginia-Bloomberg News
SMH•
T-Mobile USA To Lay Off 77 Workers In Washington Starting Sept 21, 2026, Warn Notice Shows
TMUS•
